1.	Phase II/III Randomized Study of Docetaxel With or Without Oblimersen (Bcl-2 Antisense Oligonucleotide; G3139 ) in Patients With Previously Treated Non-Small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: GENTA-GN304, NCI-G01-2046, UCLA-0301058, NCT00030641
2.	Phase III Randomized Study of Dacarbazine With or Without Oblimersen (G3139) in Patients With Advanced Malignant Melanoma Phase: Phase III Type: Treatment Status: Closed Age: Any age Sponsor: Pharmaceutical / Industry Protocol IDs: GENTA-GM301, UCLA-0207109, NCT00016263
3.	Phase III Randomized Study of Dexamethasone With or Without Oblimersen in Patients With Relapsed or Refractory Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GENTA-GMY302, UF-G-29-2001, NCT00017602
4.	Phase III Randomized Study of Fludarabine and Cyclophosphamide With or Without Oblimersen (G3139, Genasense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Phase: Phase III Type: Treatment Status: Closed Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: GENTA-GL303, UCLA-0104008, NCT00024440
5.	Daunorubicin and Cytarabine With or Without Oblimersen in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 60 and over Sponsor: NCI, Other Protocol IDs: CDR0000367323, U10CA031946, CALGB-10201, NCT00085124
6.	Trial of Dacarbazine With or Without Genasense in Advanced Melanoma Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AGENDA, GM307, NCT00518895
7.	Phase I/II Study of Oblimersen With Docetaxel in Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumors (Summary Last Modified 12/2001) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MSKCC-97096, GENTA-G3139-97/01, NCI-G97-1337, NCT00003103
8.	Phase I/II Study of Augmerosen and Irinotecan in Patients With Metastatic or Recurrent Colorectal Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: SACI-IDD-98-32, UTHSC-IDD-98-32, NCI-T98-0094, NCT00004870, T98-0094
9.	Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067557, UCCRC-10017, NCI-T98-0091, T98-0091, NCT00005032
10.	Phase I/II Study of Oblimersen in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GENTA-GL208, MDA-ID-00337, NCT00021190
11.	Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000271308, U01CA069853, P30CA054174, SACI-IDD-02-23, NCI-5793, 5793, NCT00055822
12.	Phase I/II Study of Oblimersen in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MAYO-MC0285, NCI-5826, 5826, NCT00062244
13.	Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: DM02-700, P30CA016672, MDA-DM-02700, NCI-6023, CDR0000305817, 6023, NCT00063934
14.	Oblimersen, Cisplatin, and Fluorouracil in Treating Patients With Advanced Esophageal, Gastroesophageal Junction, or Stomach Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Over 18 Sponsor: NCI, Other Protocol IDs: CDR0000310160, P30CA013330, AECM-0266, NCI-5835, AECM-0302032, 5835, NCT00064259
15.	Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GL217, NCT00078234
16.	Phase I/II Study of Oblimersen in Combination With Rituximab, Ifosfamide, Carboplatin, and Etoposide in Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-12975A, 6243, NCI-6243, NCT00086944
17.	Phase II Study of Oblimersen and Gemtuzumab Ozogamicin in Elderly Patients With Relapsed Acute Myeloid Leukemia Phase: Phase II Type: Treatment Status: Closed Age: 60 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GENTA-GA210, UCCRC-10928, NCT00017589
18.	Combination Chemotherapy With or Without Oblimersen in Treating Patients With Extensive-Stage Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000069489, U10CA031946, CALGB-30103, NCT00042978
19.	Phase II Study of Oblimersen and Doxorubicin in Patients With Advanced Hepatocellular Carcinoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: PMH-PHL-011, NCI-5798, NCT00047229, 5798
20.	Oblimersen Plus Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia Phase: Phase II Type: Treatment Status: Completed Age: 15 and over Sponsor: NCI, Other Protocol IDs: CDR0000257816, U10CA031946, CALGB-10107, NCT00049192
21.	Oblimersen and Rituximab in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: ID02-148, P30CA016672, MDA-ID-02148, NCI-5808, CDR0000270426, 5808, NCT00054639
22.	Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000298756, P30CA033572, CCC-PHII-42, CHNMC-PHII-42, NCI-5828, 5828, NCT00059813
23.	Phase II Study of Oblimersen in Patients With Metastatic or Recurrent Merkel Cell Carcinoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-03105, NCI-5907, 5907, NCT00079131
24.	Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: EORTC-30021, AVENTIS-AVE3139E/2501, NCT00085228
25.	Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000258058, MSGCC-210421, NCI-5824, 5824, NCT00049374